kw1986 schreef op 24 februari 2021 19:34:www.voxmarkets.co.uk/rns/announcement...
Novacyt S.A. - Correction: Research and Development Update
24th February 2021, 19:30
RNS Number : 2611Q
24 February 2021
("Novacyt", the "Company" or the "Group")
Correction: Research and Development Update
This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8:00am CET on 24 February 2021.
Under the subtitle 'Launch of CE Mark COVID-HT Direct'
· Novacyt announces the launch of its next generation high-throughput PCR test for COVID-19 (COVID-HT Direct), which has been CE Mark approved using independent validated data.
· The new COVID-HT Direct uses pharyngeal swabs collected in viral transport media (without guanidine) and saline
Under the subtitle 'Successful completion and publication of TVG validation of PROmate™'
· This TVG accreditation supports the use of the q16/q32 and PROmate™ system in a near patient setting, and its current deployment across the NHS and to international markets.
All other information remains unchanged. The full corrected announcement is included below.